MDACC Study No:2013-0208 ( NCT No: NCT01968213)
Title:A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Principal Investigator:Robert Coleman
Treatment Agent:Rucaparib
Study Status:Open
Study Description:The goal of this clinical research study is to learn if and for how long CO-338
(rucaparib) may be able to help control ovarian, primary peritoneal, and
Fallopian tube cancer. Researchers also want to learn if biomarkers (for
example, certain changes in the DNA, the genetic material in cells) in samples
of your tumor tissue and blood can help researchers predict how you may respond
to rucaparib. The safety of this drug will also be studied.

Some participants will receive a placebo. A placebo is not a drug. It looks
like the study drug but is not designed to treat any disease or illness. It is
designed to be compared with a study drug to learn if the study drug has any
real effect.
Hide details for General InformationGeneral Information

Disease Group:Gynecology
Phase of Study:Phase III
Treatment Agents:Rucaparib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Clovis Oncology, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Robert Coleman
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-745-3357
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults